SCHEMBL30004351

SCHEMBL30004351

Nc1cc(Cl)cc(OC(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
KCNH2 Q12809 1/20 0.34
ALDH1A1 P00352 3/20 0.32
GAA P10253 2/20 0.31
APP P05067 1/20 0.31
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22081760 1.00 CYP3A4 (0.48) CYP3A4TP53MAPTLMNAMEN1
SCHEMBL30005432 0.77 APP (0.40) MAPTALDH1A1APP
SCHEMBL19950199 0.77 APP (0.40) MAPTALDH1A1APP
SCHEMBL24803973 0.75 ALDH1A1 (0.31) MAPTALDH1A1APP
SCHEMBL1494673 0.75 ALOX15 (0.32) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL30345392 0.75 ALOX15 (0.32) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL900786 0.75 MEN1 (0.36) CYP3A4MAPTLMNAMEN1RAB9A
SCHEMBL900785 0.75 LMNA (0.36) MAPTLMNAMEN1RAB9AKMT2A
SCHEMBL14000645 0.75 LMNA (0.36) MAPTLMNAMEN1RAB9AKMT2A
SCHEMBL15864862 0.75 ALDH1A1 (0.46) CYP3A4MAPTLMNAMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4323350-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
EP-4323349-A1 ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
US-20240051936-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-02-15 US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 CN disclosed
WO-2022219407-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-10-20 WO disclosed
WO-2022219412-A1 ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 MONTE ROSA THERAPEUTICS AG (CH) 2022-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051936-A1 ISOINDOLINONE COMPOUNDS CRBN, CDR2, POU2F2 CYP3A4 1729/4885TP53 2821/4885MAPT 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.